Eli Lilly and Company: Crohn Disease trials
The registry lists 10 Crohn Disease studies with Eli Lilly and Company as lead sponsor. 6 are open to participants now and 3 have results posted.
Phase 2 5Phase 3 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's DiseaseRecruitingNCT07483099Phase 2
- A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's DiseaseRecruitingNCT07483073Phase 2
- Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightRecruitingNCT06937099Phase 3
- A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's DiseaseRecruitingNCT06226883Phase 2
- A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's DiseaseRecruitingNCT05509777Phase 3
- A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)RecruitingNCT04844606Phase 3
- A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's DiseaseActive, not recruitingNCT04232553Phase 3Results posted
- A Study of Mirikizumab (LY3074828) in Participants With Crohn's DiseaseCompletedNCT03926130Phase 3Results posted
- A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's DiseaseCompletedNCT02891226Phase 2Results posted
- VTX958 for the Treatment of Moderately to Severely Active Crohn's DiseaseTerminatedNCT05688852Phase 2